This article is more than 5 years old. Information may no longer be current.

CONRAD wins science and technology prize for vaginal gel that reduces HIV, HSV-2 infections

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A recent press release announced that CONRAD, a reproductive health research organization, received the US Agency for International Development Science and Technology Pioneers Prize for the development of tenofovir gel, which reduces HIV and herpes simplex virus-2 infections in women.

CONRAD worked with the South African government and support from the United States Agency for International Development (USAID) to determine that a vaginal gel containing antiretrovirals used before and after sex would help reduce infection. The gel was tested on 889 women living in South Africa. In 2010, positive results were presented at the International AIDS Society conference in Vienna, Austria.

CONRAD was awarded $80 million over the course of 5 years from the US President’s Emergency Plan for AIDS Relief through USAID. The financial awards will fund HIV prevention research, including licensure and implementation of tenofovir gel, development of on-demand and longer-acting microbicide leads, and development of product adherence for vagina and rectal microbicides.